319 related articles for article (PubMed ID: 33251185)
21. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
Patel D; Athar M; Jha PC
J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
23. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
25. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus.
Báez-Santos YM; Mielech AM; Deng X; Baker S; Mesecar AD
J Virol; 2014 Nov; 88(21):12511-27. PubMed ID: 25142582
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel and Highly Potent Inhibitors of SARS CoV-2 Papain-Like Protease Through Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking, Molecular Dynamics Simulations, and Biological Evaluation.
Tian X; Zhao Q; Chen X; Peng Z; Tan X; Wang Q; Chen L; Yang Y
Front Pharmacol; 2022; 13():817715. PubMed ID: 35264955
[No Abstract] [Full Text] [Related]
27. Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Ribaudo G; Yun X; Ongaro A; Oselladore E; Ng JPL; Haynes RK; Law BYK; Memo M; Wong VKW; Coghi P; Gianoncelli A
Chem Biol Drug Des; 2023 Apr; 101(4):809-818. PubMed ID: 36453012
[TBL] [Abstract][Full Text] [Related]
28. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
29. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
Lee H; Lei H; Santarsiero BD; Gatuz JL; Cao S; Rice AJ; Patel K; Szypulinski MZ; Ojeda I; Ghosh AK; Johnson ME
ACS Chem Biol; 2015 Jun; 10(6):1456-65. PubMed ID: 25746232
[TBL] [Abstract][Full Text] [Related]
30. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
31. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
32.
Srivastava R; Panda SK; Sen Gupta PS; Chaudhary A; Naaz F; Yadav AK; Ram NK; Rana MK; Singh RK; Srivastava R
J Biomol Struct Dyn; 2023 Dec; ():1-18. PubMed ID: 38147408
[TBL] [Abstract][Full Text] [Related]
33. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme.
Lindner HA; Fotouhi-Ardakani N; Lytvyn V; Lachance P; Sulea T; Ménard R
J Virol; 2005 Dec; 79(24):15199-208. PubMed ID: 16306591
[TBL] [Abstract][Full Text] [Related]
34. A chimeric virus-mouse model system for evaluating the function and inhibition of papain-like proteases of emerging coronaviruses.
Deng X; Agnihothram S; Mielech AM; Nichols DB; Wilson MW; StJohn SE; Larsen SD; Mesecar AD; Lenschow DJ; Baric RS; Baker SC
J Virol; 2014 Oct; 88(20):11825-33. PubMed ID: 25100850
[TBL] [Abstract][Full Text] [Related]
35. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.
Parmar P; Rao P; Sharma A; Shukla A; Rawal RM; Saraf M; Patel BV; Goswami D
Mol Divers; 2022 Feb; 26(1):389-407. PubMed ID: 34008129
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the Ubiquitin and ISG15 Deconjugase Activity of SARS-CoV-1 and SARS-CoV-2 Papain-Like Protease.
Nayak D; Dos Santos Bury P; Drag M; Nijkerk AN; El Oualid F; Olsen SK
Methods Mol Biol; 2023; 2591():171-188. PubMed ID: 36350549
[TBL] [Abstract][Full Text] [Related]
37. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity.
Barretto N; Jukneliene D; Ratia K; Chen Z; Mesecar AD; Baker SC
J Virol; 2005 Dec; 79(24):15189-98. PubMed ID: 16306590
[TBL] [Abstract][Full Text] [Related]
38. Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation.
Patel R; Prajapati J; Rao P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Aug; 26(4):2189-2209. PubMed ID: 34591234
[TBL] [Abstract][Full Text] [Related]
39. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.
Hosseini M; Chen W; Xiao D; Wang C
Precis Clin Med; 2021 Mar; 4(1):1-16. PubMed ID: 33842834
[TBL] [Abstract][Full Text] [Related]
40. Comparison of SARS and NL63 papain-like protease binding sites and binding site dynamics: inhibitor design implications.
Chaudhuri R; Tang S; Zhao G; Lu H; Case DA; Johnson ME
J Mol Biol; 2011 Nov; 414(2):272-88. PubMed ID: 22004941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
